Bailard Inc. Sells 681 Shares of Danaher Co. (NYSE:DHR)

Bailard Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 0.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 88,195 shares of the conglomerate’s stock after selling 681 shares during the quarter. Bailard Inc.’s holdings in Danaher were worth $22,036,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Cape Investment Advisory Inc. purchased a new position in shares of Danaher during the fourth quarter valued at approximately $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC bought a new position in Danaher in the 1st quarter worth $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in shares of Danaher in the 4th quarter worth about $42,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

DHR traded down $1.41 during midday trading on Monday, hitting $268.07. 1,143,025 shares of the company traded hands, compared to its average volume of 2,811,640. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $198.56 billion, a PE ratio of 45.44, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. The company’s 50-day moving average is $259.00 and its 200 day moving average is $254.60. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. On average, research analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Linda Filler sold 3,928 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The disclosure for this sale can be found here. Insiders have sold 38,707 shares of company stock worth $10,786,944 in the last quarter. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on DHR. Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Bank of America lifted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada increased their price objective on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Six investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.